Does anyone else think it’s odd that Northwest Bio, the company that just announced unprecedented survival results of their phase III trial in Glioblastoma, that some experts are calling the greatest advancement in the treatment of Glioblastoma in decades, is somehow not represented at the Glioblastoma Development Summit March 14-16 in Boston, for the first time in its existence?
Trailblazing Diverse Mechanisms of Action Across Improved Clinical Translation to Develop Safe, Effective & Deliverable Next Generation Therapeutics for Glioblastoma Patients
Accelerate the Practical Translation & Clinical Development of Meaningful Therapies for the Treatment of Glioblastoma & Other Life Threatening CNS Tumors
Glioblastoma continues to be one of the most devasting diseases, with a severe lack of options available for treatment. Between drug delivery challenges, inefficient preclinical models and post-treatment recurrence, this is one of the most difficult tumors to develop treatments for.
Returning as an in-person meeting after three years, leading experts in the field, from key decision makers in pharma and biotech to academic pioneers are excited to re-unite at the 4th Glioblastoma Drug Development Summit to celebrate successes, learn from failures and explore novel approaches in GBM drug development over the past 12 months.
With the space moving towards novel approaches such as CAR-T Therapy and RNA vaccines, using combinations to enhance existing therapies and the expansion of GBM AGILE, there is so much to unpack at the only meeting dedicated to discussing GBM research.
This focused summit will facilitate discussion and collaboration from all areas of the GBM community, evaluating new ways to address key challenges associated with drug development like overcoming the blood-brain-barrier, addressing emerging resistance and securing funding for drug development projects.
I will note that there are a couple of interesting speakers scheduled:
Jorge Benitez, Principal Scientist at Bristol Myers Squibb (Some may recall that Jorge Benitez tweeted, “That's a great news !!!” about Northwest Bio’s results published in JAMA a few weeks ago)
Lizabeth Leveille, Vice President and Head, Boston and European Innovation Hubs & Discovery Transactions at Merck & Co (Head of a Business Development & Licensing team focused on early-stage therapeutics as well as accessing innovative research and technologies through collaboration, licensing, or M&A in the academic, pharma, and biotech community)
Market Data 
Markets 
AI
